Sio Capital Management LLC Purchases Shares of 62,719 Merus N.V. $MRUS

Sio Capital Management LLC bought a new position in Merus N.V. (NASDAQ:MRUS) during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 62,719 shares of the biotechnology company’s stock, valued at approximately $3,299,000. Merus comprises about 1.3% of Sio Capital Management LLC’s investment portfolio, making the stock its 21st biggest holding. Sio Capital Management LLC owned about 0.08% of Merus at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of MRUS. CWM LLC lifted its stake in shares of Merus by 299.0% in the 2nd quarter. CWM LLC now owns 802 shares of the biotechnology company’s stock valued at $42,000 after purchasing an additional 601 shares during the last quarter. Caitong International Asset Management Co. Ltd increased its position in Merus by 955.3% during the first quarter. Caitong International Asset Management Co. Ltd now owns 1,794 shares of the biotechnology company’s stock valued at $76,000 after acquiring an additional 1,624 shares during the last quarter. US Bancorp DE raised its stake in shares of Merus by 324.1% in the first quarter. US Bancorp DE now owns 2,935 shares of the biotechnology company’s stock valued at $124,000 after acquiring an additional 2,243 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Merus by 15.7% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,674 shares of the biotechnology company’s stock worth $141,000 after purchasing an additional 362 shares during the period. Finally, Avanza Fonder AB grew its holdings in Merus by 14.1% during the 2nd quarter. Avanza Fonder AB now owns 3,136 shares of the biotechnology company’s stock valued at $165,000 after purchasing an additional 387 shares during the last quarter. Hedge funds and other institutional investors own 96.14% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on MRUS. Barclays reissued an “equal weight” rating and issued a $97.00 price objective (down previously from $112.00) on shares of Merus in a research note on Tuesday, September 30th. William Blair lowered Merus from a “strong-buy” rating to a “hold” rating in a research note on Monday, September 29th. Canaccord Genuity Group cut Merus from a “buy” rating to a “hold” rating and boosted their price objective for the company from $67.00 to $97.00 in a report on Monday, September 29th. Industrial Alliance Securities set a $90.00 target price on Merus in a research note on Monday, August 25th. Finally, Alliance Global Partners started coverage on shares of Merus in a research note on Monday, August 25th. They set a “buy” rating and a $90.00 target price for the company. Three research analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $93.56.

Insider Activity at Merus

In other news, VP Harry Shuman sold 8,300 shares of the company’s stock in a transaction that occurred on Tuesday, November 25th. The shares were sold at an average price of $95.92, for a total value of $796,136.00. Following the completion of the sale, the vice president owned 11,002 shares of the company’s stock, valued at approximately $1,055,311.84. This represents a 43.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 3.70% of the company’s stock.

Merus Price Performance

MRUS stock opened at $95.94 on Tuesday. Merus N.V. has a 1-year low of $33.19 and a 1-year high of $96.28. The business has a 50-day moving average price of $92.94 and a 200 day moving average price of $71.55. The company has a market capitalization of $7.28 billion, a P/E ratio of -18.10 and a beta of 1.06.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.